UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

Circulation (New York, N.Y.), 2023-01, Vol.147 (4), p.296-309

2023

Link zum Volltext

Verfügbarkeit prüfen

Einsatz von NOAK bei Hämodialysepatienten mit Vorhofflimmern: AXADIA-AFNET-8-Studie

Die Nephrologie, 2023-09, Vol.18 (5), p.319-320

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study

Gynecologic oncology, 2020-09, Vol.158 (3), p.562-569

2020

Link zum Volltext

Verfügbarkeit prüfen

MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial

Circulation (New York, N.Y.), 2022-03, Vol.145 (12), p.906-915

2022

Link zum Volltext

Verfügbarkeit prüfen

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Journal of clinical oncology, 2023-04, Vol.41 (10), p.1864-1875

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

The American journal of gastroenterology, 2021-12, Vol.116 (12), p.2399-2409

2021

Link zum Volltext

Verfügbarkeit prüfen

1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S635-S635

2023

Link zum Volltext

Verfügbarkeit prüfen

Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5

Europace (London, England), 2020-07, Vol.22 (7), p.1026-1035

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection of brain lesions after catheter ablation depends on imaging criteria: insights from AXAFA-AFNET 5 trial

Europace (London, England), 2023-12, Vol.25 (12)

2023

Link zum Volltext

Verfügbarkeit prüfen

Disturbed atrial metabolism, shear stress, and cardiac load contribute to atrial fibrillation after ablation: AXAFA biomolecule study

Europace (London, England), 2024-02, Vol.26 (2)

2024

Link zum Volltext

Verfügbarkeit prüfen

Disturbed atrial metabolism, shear stress, and cardiac load AF after ablation: AXAFA biomolecule study

Europace (London, England), 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Dynamic changes of cardiovascular biomarkers after ablation for atrial fibrillation: observations from AXAFA-AFNET5

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.263-263

2021

Link zum Volltext

Verfügbarkeit prüfen

Doubly stochastic and permutation solutions to AXA = XAX when A is a permutation matrix

Linear algebra and its applications, 2023-03, Vol.661, p.79-105

Djordjević, Bogdan D.

2023

Link zum Volltext

Verfügbarkeit prüfen

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

848 A NOVEL, PRECISION-ENGINEERED AMINO ACID COMPOSITION, AXA1665, IS SAFE, WELL-TOLERATED AND IMPROVES NEUROCOGNITION AND PHYSICAL FUNCTION IN CHILD-PUGH A AND B SUBJECTS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-796-S-796

2021

Link zum Volltext

Verfügbarkeit prüfen

CORESS is an independent charity, supported by AXA Health, the MDU and the Kirby Laing Foundation

Annals of the Royal College of Surgeons of England, 2024-03, Vol.106 (3), p.201

Corbett, H

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Blood, 2020-11, Vol.136 (Supplement 1), p.1-2

2020

Link zum Volltext

Verfügbarkeit prüfen

CORESS is an independent charity, supported by AXA Health, the MDU and the Kirby Laing Foundation

Annals of the Royal College of Surgeons of England, 2023-11, Vol.105 (8), p.772

Corbett, H

2023

Link zum Volltext

Verfügbarkeit prüfen

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study

BMJ open, 2018-09, Vol.8 (9), p.e022690

2018

Link zum Volltext

Verfügbarkeit prüfen

Green Fluorescent Protein-Tagged Bacillus axarquiensis TUBP1 Reduced Cotton Verticillium Wilt Incidence by Altering Soil Rhizosphere Microbial Communities

Current microbiology, 2021-09, Vol.78 (9), p.3562-3576

2021

Link zum Volltext

Verfügbarkeit prüfen

Solutions of the matrix inequality AXA≤?A in some partial orders

Applied mathematics and computation, 2021-05, Vol.396, Article 125940

2021

Link zum Volltext

Verfügbarkeit prüfen

An arginine aminopeptidase from marine Bacillus axarquiensis SWJSX8 and its application in improving pumpkin seed protein hydrolysis

International journal of food science & technology, 2021-09, Vol.56 (9), p.4680-4689

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer

Oncotarget, 2020-04, Vol.11 (15), p.1334-1343

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial

BMJ open, 2023-10, Vol.13 (10), p.e069742-e069742

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106.649

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29.830)
Mit Volltextzugriff
(70.179)

Publikationsform

11 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(99.290)
Deutsch
(4.399)
Japanisch
(2.139)
Spanisch
(1.690)
Rumänisch
(1.347)
Französisch
(1.183)
Latein
(656)
Italienisch
(595)
Portugiesisch
(381)
Russisch
(102)
Niederländisch
(61)
Polnisch
(34)
Türkisch
(30)
Chinesisch
(27)
Tschechisch
(22)
Ndonga
(21)
Georgisch
(18)
Hebräisch
(18)
Koreanisch
(15)

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Nexis Uni
(45.943)
Factiva
(35.466)
EBSCOhost Business Source Ultimate
(19.815)
EZB Electronic Journals Library
(15.799)
Publisher or Other Site
(13.477)
IngentaConnect
(10.821)
Jstor Complete Legacy
(6.177)
IngentaConnect Journals
(5.792)
eBooks on EBSCOhost
(5.333)
Ebook Central Perpetual and DDA
(5.267)
Springer Nature - Complete Springer Journals
(4.571)
Journals@Ovid
(3.383)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.939)
Wiley-Blackwell Full Collection
(2.767)
De Gruyter eBooks
(2.495)
Elsevier ScienceDirect Journals Complete
(2.303)
Wiley Online Library Full Collection 2018
(1.849)
Taylor & Francis
(1.725)
Springer Books
(1.703)
Taylor & Francis:Master (3349 titles)
(1.675)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Pr Newswire
(4.073)
Business Wire
(4.070)
M2 Presswire
(3.605)
Ft.Com
(3.325)
Money Marketing
(1.543)
Snl European Financials Daily
(1.278)
Financial Adviser
(1.078)
Reactions
(1.051)
The Snl Insurance Daily
(1.044)
Euroweek : The Euromarket's First Newspaper
(972)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

Einsatz von NOAK bei Hämodialysepatienten mit Vorhofflimmern: AXADIA-AFNET-8-Studie

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study

MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors

Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5

Detection of brain lesions after catheter ablation depends on imaging criteria: insights from AXAFA-AFNET 5 trial

Disturbed atrial metabolism, shear stress, and cardiac load contribute to atrial fibrillation after ablation: AXAFA biomolecule study

Disturbed atrial metabolism, shear stress, and cardiac load AF after ablation: AXAFA biomolecule study

Dynamic changes of cardiovascular biomarkers after ablation for atrial fibrillation: observations from AXAFA-AFNET5

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Doubly stochastic and permutation solutions to AXA = XAX when A is a permutation matrix

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

848 A NOVEL, PRECISION-ENGINEERED AMINO ACID COMPOSITION, AXA1665, IS SAFE, WELL-TOLERATED AND IMPROVES NEUROCOGNITION AND PHYSICAL FUNCTION IN CHILD-PUGH A AND B SUBJECTS

CORESS is an independent charity, supported by AXA Health, the MDU and the Kirby Laing Foundation

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

CORESS is an independent charity, supported by AXA Health, the MDU and the Kirby Laing Foundation

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study

Green Fluorescent Protein-Tagged Bacillus axarquiensis TUBP1 Reduced Cotton Verticillium Wilt Incidence by Altering Soil Rhizosphere Microbial Communities

Solutions of the matrix inequality AXA≤?A in some partial orders

An arginine aminopeptidase from marine Bacillus axarquiensis SWJSX8 and its application in improving pumpkin seed protein hydrolysis

A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer

Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial

Suchergebnisse filtern